Want to see HK:6996 full AI Analyst Report?
6996 Stock Chart & Stats
HK$5.27
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.27
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.76 - HK$8.16
Previous CloseN/A
Volume1.25M
Average Volume (3M)1.88M
Market Cap
HK$2.50B
Enterprise ValueHK$1.85K
Total Cash (Recent Filing)HK$734.29M
Total Debt (Recent Filing)HK$257.51M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Aug 21, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding679,446,660
10 Day Avg. Volume1,689,397
30 Day Avg. Volume1,876,149
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.90Price Target Upside87.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.49
Revenue Forecast (FY)HK$708.35M
Bulls Say, Bears Say
Bulls Say
Diversified Asia CommercializationAntengene’s business model combines product sales, licensing/collaboration income, and services with a stated commercialization focus in Asia. This multi-channel revenue mix and regional commercialization capability support durable market access and recurring revenue potential as approved assets scale across geographies.
Improving Revenue TrajectoryA clear step-up in top-line growth (≈21.6% in 2025) indicates stronger commercial execution and product uptake. Sustained revenue improvement reduces reliance on financing, helps absorb fixed R&D and SG&A costs over time, and is a durable indicator of progressing toward eventual cash-flow breakeven if trends persist.
Low Leverage / Balance-sheet FlexibilityRelatively low and improving leverage provides financial flexibility to fund ongoing clinical development and commercialization through debt if needed. Modest debt levels reduce near-term solvency risk and give management optionality for strategic investments or licensing deals without immediate refinancing pressure.
Bears Say
Sustained Cash BurnDespite improvements, the company continues to generate substantial negative operating and free cash flow, meaning operations are funded externally. Persistent cash burn creates ongoing dilution or refinancing risk, limits runway for programs, and constrains ability to scale commercialization without fresh capital.
Deep Operating And Net LossesSignificant negative operating and net margins reflect that current revenues are insufficient to cover R&D and commercialization costs. Continued unprofitability increases dependency on external funding, can delay reinvestment returns, and raises execution risk for late-stage trials and market expansion over the medium term.
Eroding Equity / Negative ReturnsDeclining equity and a sharply negative ROE indicate capital erosion from persistent losses. A weakening capital base impairs the company’s ability to absorb setbacks, may increase cost of capital, and limits strategic optionality, making funding future trials and commercialization more dilutive or expensive.
Antengene Corporation Limited News
6996 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
Antengene Corporation Limited lowest stock price was HK$2.76 and its highest was HK$8.16 in the past 12 months.
What is Antengene Corporation Limited’s market cap?
Antengene Corporation Limited’s market cap is HK$2.50B.
When is Antengene Corporation Limited’s upcoming earnings report date?
Antengene Corporation Limited’s upcoming earnings report date is Aug 21, 2026 which is in 14 days.
How were Antengene Corporation Limited’s earnings last quarter?
Antengene Corporation Limited released its earnings results on Mar 20, 2026. The company reported -HK$0.302 earnings per share for the quarter, the consensus estimate of -HK$0.302 by HK$0.
Is Antengene Corporation Limited overvalued?
According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued.
Does Antengene Corporation Limited pay dividends?
Antengene Corporation Limited does not currently pay dividends.
What is Antengene Corporation Limited’s EPS estimate?
Antengene Corporation Limited’s EPS estimate is 0.43.
How many shares outstanding does Antengene Corporation Limited have?
Antengene Corporation Limited has 679,446,660 shares outstanding.
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Antengene Corporation Limited reported an EPS of -HK$0.302 in its last earnings report, expectations of -HK$0.302. Following the earnings report the stock price went up 0.247%.
Which hedge fund is a major shareholder of Antengene Corporation Limited?
Currently, no hedge funds are holding shares in HK:6996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antengene Corporation Limited
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
6996 Stock 12 Month Forecast
Average Price Target
HK$9.90
▲(87.86% Upside)
Technical Analysis
Innovent Biologics
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―